MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients

MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients

(2014) M Pichler et al.   BRITISH JOURNAL OF CANCER

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing

(2014) Sumitra Mohan et al.   PLoS Genetics

Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing

(2013) E. Heitzer et al.   CANCER RESEARCH

Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues

(2013) Qing-He Zhang et al.   GENE

Beyond Exon 2 — The Developing Story of RAS Mutations in Colorectal Cancer

(2013) Jordan Berlin   NEW ENGLAND JOURNAL OF MEDICINE

Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells

(2012) Maria I. Almeida et al.   GASTROENTEROLOGY

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

(2011) S Weidlich et al.   BRITISH JOURNAL OF CANCER

Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer

(2011) A. N. Bartley et al.   CLINICAL CANCER RESEARCH

miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer

(2011) Yanlei Ma et al.   GUT

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

(2010) Andrey Loboda et al.   BMC Medical Genomics

miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer

(2010) S. Yu et al.   CANCER RESEARCH

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma

(2010) Hiromitsu Hatakeyama et al.   PLoS One

Unregulated miR-96 Induces Cell Proliferation in Human Breast Cancer by Downregulating Transcriptional Factor FOXO3a

(2010) Huanxin Lin et al.   PLoS One

Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial Cancer

(2009) S. S. Myatt et al.   CANCER RESEARCH

Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors

(2009) Martin Pichler et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Analyzing real-time PCR data by the comparative CT method

(2008) Thomas D Schmittgen et al.   Nature Protocols

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE